A. S. Sharenkova
A. S. Sharenkova has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Sergey S. Lebedev
Russian Medical Academy of Continuous Professional Education
4 shared publications - V. M. Kulushev
Botkin Hospital
4 shared publications - Zurab Antonovich Bagateliya
Botkin Hospital
4 shared publications - Dmitriy N. Grekov
Botkin Hospital
3 shared publications - Konstantin S. Titov
Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin; Peoples' Friendship University of Russia named after Patrice Lumumba
3 shared publications - Aleksey V. Shabunin
S.P. Botkin City Clinical Hospital; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
2 shared publications
Latest Publications
- 11 December 2025
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 14 (6)
Analysis of comorbidities in patients with locally advanced colon cancer
Colon cancer is one of the five most common cancers worldwide and is more common in elderly patients who, in addition to the primary cancer, often have a number of other concomitant diseases. Objective. Detailed analysis of the structure of concomitant diseases in patients with locally advanced colon cancer. Material and methods. A prospective study involving 254 patients with locally advanced colon cancer (cT4N0M0, cT1-4N1-2M0) was conducted at the Botkin Hospital. Statistical analysis of the data was performed using RStudio software (version 4.3.3). A phenotypic disease network (PDN) was constructed with the calculation of the cosine index value for all possible pairs of comorbidities. Results. Concomitant diseases were detected in 96.5% of patients. The most common diseases were arterial hypertension (68.9%), obesity (61.0%), anemia (50.0%), gastritis, gastric ulcer and duodenal ulcer (32.3%), and coronary heart disease (30.3%). Women had a greater number of concomitant diseases compared to men (median 4.0 and 3.0, respectively, p=0.009). Women more often had hypertension (74.2%), gastrointestinal diseases (39.5%) and thyroid gland diseases (19.7%), while men had COPD (5.6%). A total of 112 pairs of concomitant diseases were obtained. The minimum cosine index value was 0.047 for the pair CKD + cardiomyopathy, the maximum was 0.697 for the pair hypertension + obesity. Five pairs of comorbidities with a cosine index value of more than 0.5 were identified: hypertension + obesity (cosine index 0.697), hypertension + anemia (cosine index 0.618), hypertension + coronary heart disease (cosine index 0.593), anemia + obesity (cosine index 0.555), hypertension + gastric ulcer and duodenal ulcer, gastritis (cosine index 0.507). Conclusion. Most patients with colon cancer have a number of concomitant diseases that coexist in various combinations. Their correction in specialized departments will allow choosing the most optimal treatment option taking into account a personalized approach, which, in the future, can improve the prognosis of comorbid patients with locally advanced colon cancer.
- 11 December 2025
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 14 (6)
Analysis of comorbidities in patients with locally advanced colon cancer
Colon cancer is one of the five most common cancers worldwide and is more common in elderly patients who, in addition to the primary cancer, often have a number of other concomitant diseases. Objective. Detailed analysis of the structure of concomitant diseases in patients with locally advanced colon cancer. Material and methods. A prospective study involving 254 patients with locally advanced colon cancer (cT4N0M0, cT1-4N1-2M0) was conducted at the Botkin Hospital. Statistical analysis of the data was performed using RStudio software (version 4.3.3). A phenotypic disease network (PDN) was constructed with the calculation of the cosine index value for all possible pairs of comorbidities. Results. Concomitant diseases were detected in 96.5% of patients. The most common diseases were arterial hypertension (68.9%), obesity (61.0%), anemia (50.0%), gastritis, gastric ulcer and duodenal ulcer (32.3%), and coronary heart disease (30.3%). Women had a greater number of concomitant diseases compared to men (median 4.0 and 3.0, respectively, p=0.009). Women more often had hypertension (74.2%), gastrointestinal diseases (39.5%) and thyroid gland diseases (19.7%), while men had COPD (5.6%). A total of 112 pairs of concomitant diseases were obtained. The minimum cosine index value was 0.047 for the pair CKD + cardiomyopathy, the maximum was 0.697 for the pair hypertension + obesity. Five pairs of comorbidities with a cosine index value of more than 0.5 were identified: hypertension + obesity (cosine index 0.697), hypertension + anemia (cosine index 0.618), hypertension + coronary heart disease (cosine index 0.593), anemia + obesity (cosine index 0.555), hypertension + gastric ulcer and duodenal ulcer, gastritis (cosine index 0.507). Conclusion. Most patients with colon cancer have a number of concomitant diseases that coexist in various combinations. Their correction in specialized departments will allow choosing the most optimal treatment option taking into account a personalized approach, which, in the future, can improve the prognosis of comorbid patients with locally advanced colon cancer.
- Open Access
- 4 November 2025
- Published by Institute of Cytology and Genetics, SB RAS in Siberian Scientific Medical Journal
- Vol. 45 (5) , 291-300
The role of neoadjuvant chemotherapy in the treatment of locally advanced colon cancer in comorbid patients
Colon cancer is one of the most common cancers in the world. In most patients, a locally advanced process is detected, which requires careful selection of optimal management tactics. In this connection, neoadjuvant chemotherapy (NACHT) is being actively introduced into clinical practice. Aim of the study was to evaluate the effectiveness of NACHT in comorbid patients with locally advanced colon cancer. Material and methods . The study was prospective and randomized, it included 254 patients with locally advanced colon cancer (cT4N0M0, cT1-4N1-2M0). Various comorbidities were detected in 96.5 % of patients. The final analysis included 53 patients from the NACHT + ACHT group and 98 patients receiving only ACHT. Statistical data processing was performed using RStudio software (version 2024.12.1+563) in the R programming language. Results. Disease progression was significantly more frequent in patients receiving NACHT + ACHT compared to patients in the ACHT group: 35.3 and 19.6 %, respectively (p = 0.036). In addition, patients receiving NACHT + ACHT progressed faster than patients receiving ACHT only: the median time without progression was 10.0 and 12.0 months, respectively (p = 0.033). The 3-year relapse-free survival rate was lower in the NACHT + ACHT group than in patients who underwent surgery followed by ACHT at the first stage – 40 and 76 %, respectively (р = 0,000). Cox regression analysis showed that the use of NACHT at the first stage of treatment in comorbid patients with locally advanced colon cancer increases the risk of progression by 3.912 times, regardless of the stage of the disease (hazard ratio = 3.912; 95 % confidence interval 1.859–8.232; p < 0.001). Conclusions . For comorbid patients with locally advanced colon cancer, it is most advisable to perform surgery at the first stage of treatment without prior NACHT, which is associated with a higher risk of disease progression regardless of the stage. The obtained results may be related to the increased time to surgery due to the administration of NACHT, which creates a potential temporal "window" for the maintenance of the tumor process.
- 4 November 2025
- Published by Institute of Cytology and Genetics, SB RAS in Siberian Scientific Medical Journal
- Vol. 45 (5) , 291-300
Open AccessThe role of neoadjuvant chemotherapy in the treatment of locally advanced colon cancer in comorbid patients
Colon cancer is one of the most common cancers in the world. In most patients, a locally advanced process is detected, which requires careful selection of optimal management tactics. In this connection, neoadjuvant chemotherapy (NACHT) is being actively introduced into clinical practice. Aim of the study was to evaluate the effectiveness of NACHT in comorbid patients with locally advanced colon cancer. Material and methods . The study was prospective and randomized, it included 254 patients with locally advanced colon cancer (cT4N0M0, cT1-4N1-2M0). Various comorbidities were detected in 96.5 % of patients. The final analysis included 53 patients from the NACHT + ACHT group and 98 patients receiving only ACHT. Statistical data processing was performed using RStudio software (version 2024.12.1+563) in the R programming language. Results. Disease progression was significantly more frequent in patients receiving NACHT + ACHT compared to patients in the ACHT group: 35.3 and 19.6 %, respectively (p = 0.036). In addition, patients receiving NACHT + ACHT progressed faster than patients receiving ACHT only: the median time without progression was 10.0 and 12.0 months, respectively (p = 0.033). The 3-year relapse-free survival rate was lower in the NACHT + ACHT group than in patients who underwent surgery followed by ACHT at the first stage – 40 and 76 %, respectively (р = 0,000). Cox regression analysis showed that the use of NACHT at the first stage of treatment in comorbid patients with locally advanced colon cancer increases the risk of progression by 3.912 times, regardless of the stage of the disease (hazard ratio = 3.912; 95 % confidence interval 1.859–8.232; p < 0.001). Conclusions . For comorbid patients with locally advanced colon cancer, it is most advisable to perform surgery at the first stage of treatment without prior NACHT, which is associated with a higher risk of disease progression regardless of the stage. The obtained results may be related to the increased time to surgery due to the administration of NACHT, which creates a potential temporal "window" for the maintenance of the tumor process.
- 29 October 2025
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 14 (5) , 19-25
Efficacy of neoadjuvant chemotherapy in locally advanced colon cancer
The generally accepted strategy for treating locally advanced colon cancer is radical surgery involving resection of the colonic portion with the tumor and lymphadenectomy followed by adjuvant chemotherapy. The issue of increasing the metabolic activity of micrometastases and tumor seeding after removal of the primary tumor remains relevant. Objective. To study the efficacy and safety of neoadjuvant chemotherapy (NACHT) in patients with locally advanced resectable colon cancer. Material and methods. The medical records of 90 patients at the Botkin Hospital from January 1, 2022 to January 1, 2024 with colon adenocarcinoma. with stage cT3 or higher and/or involvement of regional lymph nodes (cN+) regardless of the T value, with the absence of MSI (microsatellite instability), without distant metastasis and with chemotherapy in the XELOX, FOLFOX and FOLFOXIRI regimens were retrospectively analyzed. Results. A full course of NACHT was completed by 83 patients (92.2%) without progression and/or grade III–IV complications. Progression was observed in three patients (3.3%). Surgical treatment was performed in all patients, R0 resections were achieved in 100% of cases. Adjuvant chemotherapy was not received by 29 patients (32.2%). Toxicity during NACHT was observed in 34 cases (37.7%). The incidence of grade III–IV complications was 5 (5.1%). Complete therapeutic pathomorphosis was observed in 3 patients (3.3%), partial tumor response in 39 (43.3%). The median follow-up was 23.1 months, the incidence of progression was 10 months (11.1%). Local relapse was observed in 3 patients (3%), distant metastases — in 7 patients (8%). The 2-year overall and relapse-free survival rates were 94 and 92.8%, respectively. Conclusion. NACNT is safe and effective for patients with colon cancer: tolerability is satisfactory, the risk of progression is minimal, and the incidence of postoperative complications is comparable with the results of the world literature. Prospective comparative studies are needed to further study this topic.
- 29 October 2025
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 14 (5) , 19-25
Efficacy of neoadjuvant chemotherapy in locally advanced colon cancer
The generally accepted strategy for treating locally advanced colon cancer is radical surgery involving resection of the colonic portion with the tumor and lymphadenectomy followed by adjuvant chemotherapy. The issue of increasing the metabolic activity of micrometastases and tumor seeding after removal of the primary tumor remains relevant. Objective. To study the efficacy and safety of neoadjuvant chemotherapy (NACHT) in patients with locally advanced resectable colon cancer. Material and methods. The medical records of 90 patients at the Botkin Hospital from January 1, 2022 to January 1, 2024 with colon adenocarcinoma. with stage cT3 or higher and/or involvement of regional lymph nodes (cN+) regardless of the T value, with the absence of MSI (microsatellite instability), without distant metastasis and with chemotherapy in the XELOX, FOLFOX and FOLFOXIRI regimens were retrospectively analyzed. Results. A full course of NACHT was completed by 83 patients (92.2%) without progression and/or grade III–IV complications. Progression was observed in three patients (3.3%). Surgical treatment was performed in all patients, R0 resections were achieved in 100% of cases. Adjuvant chemotherapy was not received by 29 patients (32.2%). Toxicity during NACHT was observed in 34 cases (37.7%). The incidence of grade III–IV complications was 5 (5.1%). Complete therapeutic pathomorphosis was observed in 3 patients (3.3%), partial tumor response in 39 (43.3%). The median follow-up was 23.1 months, the incidence of progression was 10 months (11.1%). Local relapse was observed in 3 patients (3%), distant metastases — in 7 patients (8%). The 2-year overall and relapse-free survival rates were 94 and 92.8%, respectively. Conclusion. NACNT is safe and effective for patients with colon cancer: tolerability is satisfactory, the risk of progression is minimal, and the incidence of postoperative complications is comparable with the results of the world literature. Prospective comparative studies are needed to further study this topic.
- 9 April 2025
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 4,p. 71-78
Comparative analysis of longitudinal and transverse minilaparotomy during colon cancer surgery
Background. The steady increase in the incidence of colorectal cancer and its early diagnosis contribute to the identification of resectable forms of this disease, which in turn increases the number of minimally invasive surgical interventions. Therefore, the question of studying the influence of risk factors for the development of hernias and the search for an “ideal” place on the abdominal wall, which would provide the most convenient access for safe removal of the macropreparation and subsequent extracorporeal surgical procedures, as well as a low incidence of wound complications and postoperative ventral hernias, is the most pressing issue in colon cancer surgery. Objective. To study the differences in the incidence of postoperative ventral hernias during transabdominal extraction of the specimen depending on the type of access after minimally invasive colon resections for cancer, and to evaluate the risk factors for the occurrence of postoperative hernias. Material and methods. We retrospectively analyzed the medical records of 216 patients who underwent colon resection at the Botkin Medical Scientific and Clinical Center from January 2022 to September 2023. We used a cohort study to determine the impact of the type of access after minimally invasive colon resections for cancer on the incidence of postoperative ventral hernias. The formation of postoperative hernias was detected when longitudinal minilaparotomy was used for the extracorporeal stage of the operation or extraction of the removed preparation. Results. Of the 216 patients included in the study, 3 patients dropped out according to the exclusion criteria, so 213 patients were analyzed. Median criteria for operative time and blood loss did not differ (p>0.05) in both groups. There were no differences depending on the technique of videoendoscopic intervention used p=(0.762). A strong tendency to use a longitudinal approach was also observed when performing minimally invasive right hemicolectomy (p=0.051), and for distal colon resections, Pfanenstiel minilaparotomy was performed significantly more often (p=0.047). Among patients who underwent transverse minilaparotomy for the extracorporeal stage of surgery or extraction of the removed specimen, hernias in the incision area did not develop (p=0.0001), and in the longitudinal minilaparotomy group, hernias in the area of the access performed were detected in 21.9% of the operated patients. Conclusion. In our study, patients who underwent minimally invasive radical surgery for colon cancer using the longitudinal minilaparotomy method had a higher risk of hernia compared with patients who underwent surgery using transverse approaches.
- 9 April 2025
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 4,p. 71-78
Comparative analysis of longitudinal and transverse minilaparotomy during colon cancer surgery
Background. The steady increase in the incidence of colorectal cancer and its early diagnosis contribute to the identification of resectable forms of this disease, which in turn increases the number of minimally invasive surgical interventions. Therefore, the question of studying the influence of risk factors for the development of hernias and the search for an “ideal” place on the abdominal wall, which would provide the most convenient access for safe removal of the macropreparation and subsequent extracorporeal surgical procedures, as well as a low incidence of wound complications and postoperative ventral hernias, is the most pressing issue in colon cancer surgery. Objective. To study the differences in the incidence of postoperative ventral hernias during transabdominal extraction of the specimen depending on the type of access after minimally invasive colon resections for cancer, and to evaluate the risk factors for the occurrence of postoperative hernias. Material and methods. We retrospectively analyzed the medical records of 216 patients who underwent colon resection at the Botkin Medical Scientific and Clinical Center from January 2022 to September 2023. We used a cohort study to determine the impact of the type of access after minimally invasive colon resections for cancer on the incidence of postoperative ventral hernias. The formation of postoperative hernias was detected when longitudinal minilaparotomy was used for the extracorporeal stage of the operation or extraction of the removed preparation. Results. Of the 216 patients included in the study, 3 patients dropped out according to the exclusion criteria, so 213 patients were analyzed. Median criteria for operative time and blood loss did not differ (p>0.05) in both groups. There were no differences depending on the technique of videoendoscopic intervention used p=(0.762). A strong tendency to use a longitudinal approach was also observed when performing minimally invasive right hemicolectomy (p=0.051), and for distal colon resections, Pfanenstiel minilaparotomy was performed significantly more often (p=0.047). Among patients who underwent transverse minilaparotomy for the extracorporeal stage of surgery or extraction of the removed specimen, hernias in the incision area did not develop (p=0.0001), and in the longitudinal minilaparotomy group, hernias in the area of the access performed were detected in 21.9% of the operated patients. Conclusion. In our study, patients who underwent minimally invasive radical surgery for colon cancer using the longitudinal minilaparotomy method had a higher risk of hernia compared with patients who underwent surgery using transverse approaches.